IL7 and Sepsis: The present study confirms and extends findings from our earlier investigation [14] demonstrating that administration of a glycosylated recombinant human IL-7 (CYT107) can effectively reverse the profound sepsis-induced lymphopenia that is a defining pathophysiologic hallmark of sepsis [1–5, 15, 16].